Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:301033's EV-to-FCF is ranked worse than 66.91% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 22.87
vs SZSE:301033: 34.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medprin Regenerative Medical Technologies Co (SZSE:301033) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medprin Regenerative Medical Technologies Co's PE Ratio (TTM) for today is calculated as:
Medprin Regenerative Medical Technologies Co's share price for today is ¥52.96.
Medprin Regenerative Medical Technologies Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.828.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medprin Regenerative Medical Technologies Co EV-to-FCF Related Terms
Medprin Regenerative Medical Technologies Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co EV-to-FCF Chart
Medprin Regenerative Medical Technologies Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medprin Regenerative Medical Technologies Co EV-to-FCF vs Medical Devices & Instruments Industry
Medprin Regenerative Medical Technologies Co's current Enterprise Value is ¥3,279.5 Mil.
Medprin Regenerative Medical Technologies Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥96.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medprin Regenerative Medical Technologies Co (SZSE:301033) has a EV-to-FCF of 34.06 as of Sep. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. This is near median its historical median of 33.06. According to the industry distribution chart, Medprin Regenerative Medical Technologies Co ranks #279 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 66.9%.
Is Medprin Regenerative Medical Technologies Co's EV-to-FCF too high?
Medprin Regenerative Medical Technologies Co's current EV-to-FCF of 34.06 is near median its 10-year median of 33.06. The Medical Devices & Instruments industry median EV-to-FCF is 22.87. Medprin Regenerative Medical Technologies Co's value of 34.06 is 48.9% above this industry median. Based on the distribution chart, Medprin Regenerative Medical Technologies Co ranks #279 out of 417 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medprin Regenerative Medical Technologies Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medprin Regenerative Medical Technologies Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medprin Regenerative Medical Technologies Co ranks #279 out of 417 companies for EV-to-FCF. This places Medprin Regenerative Medical Technologies Co in the lower half of its industry. The industry median EV-to-FCF is 22.87. Medprin Regenerative Medical Technologies Co's value of 34.06 is 48.9% above this benchmark. While the company's 10-year median is 33.06 vs. the industry median of 22.87, Medprin Regenerative Medical Technologies Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.87, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medprin Regenerative Medical Technologies Co's current EV-to-FCF of 34.06 is 48.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medprin Regenerative Medical Technologies Co's current EV-to-FCF is 34.06, which is near median its own 10-year median of 33.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medprin Regenerative Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co (SZSE:301033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥73.38, compared to a current price of ¥52.96 — trading 27.8% below its estimated fair value. The current EV-to-FCF is 34.06, which is near median its 10-year median of 33.06 and 48.9% above the Medical Devices & Instruments industry median of 22.87. Medprin Regenerative Medical Technologies Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medprin Regenerative Medical Technologies Co (SZSE:301033), the current EV-to-FCF is 34.06 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medprin Regenerative Medical Technologies Co (SZSE:301033) Overvalued in 2026?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co stock appears to be undervalued.
The current stock price of ¥52.96 is trading 27.8% below its estimated GF Value™ of ¥73.38.
GuruFocus considers Medprin Regenerative Medical Technologies Co to be Modestly Undervalued.
Key valuation signals for SZSE:301033:
EV-to-FCF: 34.06 (near median its 10-year median of 33.06)
GF Value™: ¥73.38 vs. price of ¥52.96 (27.8% below fair value)
Industry Position: 48.9% above the Medical Devices & Instruments median (#279 of 417)
No single metric tells the full story. See the SZSE:301033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301033 has been successfully added to your 
